This report provides a compilation and analysis of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2024. In addition, publicly available 2024 sales data of biosimilar antibodies and proteins as well as of new biologic modalities such as gene and cell therapy and RNA (antisense, siRNA) are included in the report.
Sales data were obtained from company disclosures with cut-off date March 6, 2025. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of January 30, 2025. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates are presented as reported (in very few cases as constant exchange rates). Fiscal years different from the calendar year 2024 were re-calculated to calendar year 2024 sales.
Sales data from nearly 400 products form the basis of the report. 2024 sales data from 36 products have been added for the first time to the compilation.
Individual product sales data are presented within the following groups:
- Cancer Antibodies
- Non-TNF Anti-Inflammatory mAbs
- Cardiometabolic Antibodies
- Anti-TNF Antibodies
- Ophthalmic Antibodies
- Insulin & Insulin Analogs
- Coagulation Factors
- Enzyme Replacement Therapy
- Neuromodulators (botulinumtoxins)
- Established Therapeutic Proteins
- Anti-Infective Antibodies
- Migraine Antibodies
- Other Proteins
- Biosimilar Antibodies & Proteins
- Gene, Cell & RNA Therapy
In the analytical part of the report, sales data from 2012 to 2024 are summarized for the class of products and their growth rates reported. The percentage of antibody sales of total biologics sales was calculated. The time course of sales of established therapeutic proteins (erythropoietins, interferon, G-CSF, hGH and FSH) are presented for the period of 2012-2024.
Sales and growth rates of cancer antibodies were analyzed by subgroup:
- Anti-PD-1 & PD-L1 Antibodies (Abs)
- Other Immuno-Oncology (I-O) Abs
- Anti-Her2 Abs
- Anti-EGFR Abs
- Anti-VEGF/-R Abs
- Anti-CD20 Abs
- Other Cancer Abs
In addition, 2024 sales data of target-specific cancer antibodies were calculated for PD-1; PD-L1; PD-1 x LAG3 FDC; PD-1 x CTLA4; PD-1 x VEGF; CD38; CTLA4; CD19 (x CD3); CCR4; Cell-Surface Glycoprotein CS1; RANKL; Nectin-4; CD30; TROP-2; CD79b; BCMA (x CD3); Folate Receptor 1; gp100 (x CD3); Ganglioside GD2; Interleukin-6; Tissue Factor; DLL3; CLDN18.2; IL-2Rβ/γ (IL-15 superagonist).
Sales and growth rates of non-TNF anti-inflammatory antibodies were analyzed by therapeutic area:
- Dermatology
- Rheumatoid & Autoimmune
- Neuro-Inflammation
- Pulmonary & Respiratory
- Gastrointestinal
In addition, 2024 sales data of target-specific non-TNF anti-inflammatory antibodies were calculated for Interleukin-4 Receptor (IL-4R); p40 of IL-12/2;, p19 of IL-23; IL-17(R); IL-13; IL-31; Complement C5; B7-1 & B7-2 (CD80 & CD86); IL-6 Receptor; IL-1; BLyS +/- APRIL; Interferon alpha Receptor; Interferon gamma; Complement protein component 1 (C1s); CD20; FcRn; IL-5 (Receptor); IgE; TSLP; α4/β7 integrin; α4/β1/7 integrin.
To highlight commercial success of novel antibody drug modalities, development of sales and growth rates of antibody-drug conjugates and of bispecific antibodies are shown for the years 2012/2015 to 2024.
Company specific sales data for biosimilar antibodies and proteins are highlighted in a Table for the years 2020 to 2023 as far as published which allows a ranking of biosimilar companies based on total biosimilar revenues.
Total sales for novel biologic drug modalities, i.e. gene and cell therapy and RNA-based biologics (antisense, siRNA, PMOs), are presented and were considered if published.
Sales of innovator therapeutic antibodies and proteins were summarized per company and a ranking list was prepared for the TOP 30 companies regarding biologics sales in 2024.
A total of 75 innovator therapeutic antibodies and proteins reached blockbuster status with 2024 sales exceeding US$ 1 billion, two drop outs were observed.
Table of Contents
Currency Exchange Rates
